GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (OTCPK:AINMF) » Definitions » ROE %

NetraMark Holdings (NetraMark Holdings) ROE % : -687.01% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NetraMark Holdings's annualized net income for the quarter that ended in Mar. 2024 was $-2.12 Mil. NetraMark Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $0.31 Mil. Therefore, NetraMark Holdings's annualized ROE % for the quarter that ended in Mar. 2024 was -687.01%.

The historical rank and industry rank for NetraMark Holdings's ROE % or its related term are showing as below:

AINMF' s ROE % Range Over the Past 10 Years
Min: -308.16   Med: -135.79   Max: -15.98
Current: -62.34

During the past 4 years, NetraMark Holdings's highest ROE % was -15.98%. The lowest was -308.16%. And the median was -135.79%.

AINMF's ROE % is ranked worse than
88.03% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.485 vs AINMF: -62.34

NetraMark Holdings ROE % Historical Data

The historical data trend for NetraMark Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings ROE % Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
ROE %
-16.00 -104.89 -163.27 -304.29

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.10 -70.35 - -406.07 -687.01

Competitive Comparison of NetraMark Holdings's ROE %

For the Health Information Services subindustry, NetraMark Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's ROE % falls into.



NetraMark Holdings ROE % Calculation

NetraMark Holdings's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %=Net Income (A: Sep. 2023 )/( (Total Stockholders Equity (A: Sep. 2022 )+Total Stockholders Equity (A: Sep. 2023 ))/ count )
=-10.472/( (6.081+0.802)/ 2 )
=-10.472/3.4415
=-304.29 %

NetraMark Holdings's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-2.116/( (0.451+0.165)/ 2 )
=-2.116/0.308
=-687.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


NetraMark Holdings  (OTCPK:AINMF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-2.116/0.308
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.116 / 0.656)*(0.656 / 0.518)*(0.518 / 0.308)
=Net Margin %*Asset Turnover*Equity Multiplier
=-322.56 %*1.2664*1.6818
=ROA %*Equity Multiplier
=-408.49 %*1.6818
=-687.01 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-2.116/0.308
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.116 / -2.116) * (-2.116 / -2.116) * (-2.116 / 0.656) * (0.656 / 0.518) * (0.518 / 0.308)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1 * -322.56 % * 1.2664 * 1.6818
=-687.01 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NetraMark Holdings ROE % Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (NetraMark Holdings) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.